Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Prior Auth Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy 26328

    Priority Health Medicare Prior Authorization Criteria — Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for priority health Policy 26328 alerts

    Get alerted when Policy 26328 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization, coverage duration, exclusions, required documentation, and clinical prerequisites for specified pharmacy and specialty drugs for Priority Health Medicare members. Affects prescribers requesting coverage for listed products.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Prior Authorization Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy 26328
    Change TypeNo material change
    Effective Date
    Last ReviewJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation of diagnosis, required prior therapy trials, and supporting laboratory or imaging results as specified for the requested product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Part 10–11Part of document
    ~110+Products listed (approx.)
    1-2 yrsTypical auth duration
    FrequentSpecialist required
    ManyPrior therapy required

    Coverage Criteria (Product-specific)

    ACTHAR coverage criteria

    Covered when ALL of the following are met:

    ACTHAR initial coverage: Documentation of prior therapies and responses; therapeutic trial of a parenteral glucocorticoid AND Cortrophin for all covered indications except infantile spasms; supporting documentation demonstrating inadequate response, intolerance, or FDA-labeled contraindication; quantity limited to FDA-approved dosingcoverage duration 6 weeks

    Reauthorization requires demonstrated clinical benefit.

    Adalimumab and similar biologics — class criteria and prohibitions

    Covered when ALL of the following are met:

    Adalimumab-class biologics: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; documentation of prior therapies and responses required; prescriber is a specialist or has consulted a specialist; dose must follow FDA labeling or be supported in approved compendia for Part D
    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Prior Authorization Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy 26328
    Change TypeNo material change
    Effective Date
    Last ReviewJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation of diagnosis, required prior therapy trials, and supporting laboratory or imaging results as specified for the requested product.
    SourceLink
    On This Page
    Coverage Criteria (Product-specific)Coding and Measurable ThresholdsProvider Actions, Prior Authorization & DocumentationInitial Therapy Criteria (Selected Products)Continuation / Reauthorization CriteriaStep Therapy RequirementsQuantity Limits and Dosing ConstraintsSite of Care and Prescriber QualificationsBackground and ScopeDefinitions and Clinical Thresholds
    coverage duration 2 years

    Condition-specific prior therapy requirements (RA, AS, psoriasis, HS, uveitis, JIA) apply as detailed in policy (e.g., try and fail one traditional non-biologic immunomodulator for RA).

    Aimovig criteria

    Covered when ALL of the following are met:

    Aimovig (migraine prevention) initial: Not used in combination with other CGRP antagonist therapy; initial requests require at least 4 migraine days per month; dosing must align with FDA labelinginitial approval 1 year; reauthorization 2 years

    Reauthorization requires documentation of decreased migraine days compared to baseline.

    Amvuttra HATTR-PN and ATTR-CM criteria

    Covered when ALL of the following are met:

    Amvuttra HATTR-PN initial: Genetic confirmation of a transthyretin (TTR) mutation AND baseline PND score ≤ IIIb AND clinical signs/symptoms of neuropathy AND diagnostic confirmation by tissue biopsy or genetic testing (or radionuclide imaging with Grade 2–3 uptake if imaging used)age ≥18

    Must not be used in patients with primary (light-chain) amyloidosis; reauthorization requires documentation of positive clinical response vs baseline.

    Amvuttra ATTR-CM initial: Trial and failure, intolerance, or contraindication to tafamidis (unless contraindicated) AND NYHA class I–III with clinical manifestations or prior HF hospitalization AND ECHO or CMR showing cardiac involvement AND diagnosis confirmed by biopsy, genetic testing, or radionuclide imaging (Grade 2–3 uptake if imaging used)age ≥18

    Reauthorization requires documentation of positive clinical response (e.g., reduced CV hospitalizations).

    Arikayce MAC lung disease criteria

    Covered when ALL of the following are met:

    Arikayce initial for MAC lung disease: Submit sputum culture supporting MAC diagnosis AND documented failure to obtain negative sputum cultures after ≥6 months of a multidrug background regimen; prescriber must be or consult an infectious disease specialist or pulmonologistinitial approval 6 months

    Reauthorization requires negative sputum culture within last 30 days and application of ATS/IDSA guidance.

    Benlysta SLE and lupus nephritis criteria

    Covered when ALL of the following are met:

    Benlysta SLE initial: SELENA-SLEDAI score ≥6 AND anti-dsDNA >30 IU/mL or ANA >1:80 AND patient taking two of: steroid, immunosuppressant, and/or hydroxychloroquine for ≥12 weeks each; prescriber must be a specialist or have consulted oneinitial 1 year; reauth 2 years

    For lupus nephritis initial requests: kidney biopsy confirming class 3, 4, and/or 5 disease and standard LN therapy required; reauthorization requires evidence of clinical improvement.

    Braftovi

    Covered when ALL of the following are met:

    Braftovi: Documentation of BRAF V600 mutation status requiredcoverage duration 2 years

    Covers medically-accepted indications when mutation documented.

    Brivaracetam

    Covered when ALL of the following are met:

    Brivaracetam: Documentation of trial and failure (inadequate seizure control) with generic levetiracetam AND at least one other generic anticonvulsantcoverage duration 2 years

    Prerequisite therapy required.

    Brukinsa

    Covered when ALL of the following are met:

    Brukinsa: Coverage per FDA labeling; for certain hematologic malignancies where NCCN gives same category recommendation, prescriber must justify why Calquence or Imbruvica cannot be used; coverage duration one year

    Prescriber documentation as required.

    Calcipotriene-betameth

    Covered when ALL of the following are met:

    Calcipotriene-betameth diprop external suspension: Documentation of trial and failure with a generic topical steroid for the scalp in combination with generic calcipotriene solution (failure = inadequate response)coverage duration 2 years

    Prerequisite therapy required.

    Caplyta

    Covered when ALL of the following are met:

    Caplyta: Documentation of prior therapies and responses required; age ≥18; indication-specific prior trials (e.g., trials of generic atypical antipsychotics as specified)coverage duration 2 years

    Prerequisite therapy required.

    Clobazam

    Covered when ALL of the following are met:

    Clobazam (suspension/tablet): Patient must first try one generic anticonvulsant; suspension formulation only when tablets contraindicated (e.g., dysphagia)coverage duration 2 years

    Prerequisite therapy required.

    Clozapine (dispersible)

    Covered when ALL of the following are met:

    Clozapine (dispersible): Prior trial and documented contraindication (e.g., dysphagia) to generic clozapine tablet requiredcoverage duration 1 year

    Prerequisite therapy required.

    Cobenfy

    Covered when ALL of the following are met:

    Cobenfy: Documentation of trial and failure with two generic atypical antipsychotics used ≥28 days each; age ≥18; prescribed by or in consultation with a specialistcoverage duration 2 years

    Prerequisite therapy required.

    Colistimethate

    Covered when ALL of the following are met:

    Colistimethate sodium: Use must be IV or IM; nebulization/inhalation not covered; infection must be proven or strongly suspected with culture & susceptibility OR local epidemiology; prescribed by or in consultation with infectious disease specialistcoverage duration 1 year

    Site-of-care: hospital outpatient or infusion center preferred.

    Cortrophin

    Covered when ALL of the following are met:

    Cortrophin: Initial coverage per FDA label or max 3 months if unspecified; prerequisite parenteral glucocorticoid and other agent trials required for many indications (infantile spasms exempt); quantity limited to FDA label dosing; reauthorization requires clinical benefit

    Prescriber documentation of prior trials required.

    Cosentyx — biologic criteria and prior-therapy requirements

    Covered when ALL of the following are met:

    Cosentyx: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; documentation of prior therapies and responses required; prescriber specialist involvement required; indication-specific prior trials required (e.g., NSAID for AS; traditional non-biologic immunomodulator for psoriasis)coverage duration 2 years

    Dosing per FDA label or supported compendia.

    Cresemba

    Covered when ALL of the following are met:

    Cresemba (oral): Coverage per FDA labeling; for invasive aspergillosis provide documentation supporting inability to use generic voriconazole when applicablecoverage duration 1 year

    Prescriber documentation required.

    Cystadrops / Cystaran

    Covered when ALL of the following are met:

    Cystadrops / Cystaran: Coverage for FDA-approved indications; standard documentation appliescoverage duration 2 years

    Prescriber documentation as specified.

    Dalfampridine ER

    Covered when ALL of the following are met:

    Dalfampridine ER: No history of seizure AND creatinine clearance >50 mL/min; baseline T25FW and ambulatory status required; reauthorization requires stability or improvement in walking speedinitial & reauth 1 year

    Prescriber documentation required.

    Diacomit

    Covered when ALL of the following are met:

    Diacomit: Diagnosis of seizures associated with Dravet syndrome AND not currently controlled on therapy (seizures within past 28 days) AND concomitant clobazam therapy; prescribed by or in consultation with specialistcoverage duration 2 years

    Prerequisite therapy required.

    Dihydroergotamine nasal

    Covered when ALL of the following are met:

    Dihydroergotamine nasal: Trial and failure of one non-oral triptan (e.g., sumatriptan nasal/injection) AND trial and failure of Nurtec ODT requiredcoverage duration 2 years

    Prerequisite therapy required.

    Drizalma / Duloxetine-related

    Covered when ALL of the following are met:

    Drizalma / duloxetine-related products: Documentation of inability to use duloxetine (generic) AND trial and failure with one other generic antidepressant requiredcoverage duration 2 years

    Prerequisite therapy required.

    Droxidopa

    Covered when ALL of the following are met:

    Droxidopa: Patient must first try midodrine; reauthorization requires documentation of positive clinical response (e.g., sustained decrease in dizziness)initial & reauth 1 year

    Prescriber documentation required.

    Dupixent — multiple indications and reauthorization examples

    Covered when ALL of the following are met:

    Dupixent — asthma: Oral corticosteroid-dependent asthma OR eosinophilic phenotype (blood eosinophils ≥150 cells/µL at initiation or ≥300 cells/µL past 12 months) AND trial/failure of 1 ICS/LABA in past 6 months; reauthorization requires clinical benefit vs baselineinitial 1 year; reauth 2 years

    Prescriber specialist involvement required; dosing per label.

    Dupixent — EoE: Diagnosis confirmed by esophageal biopsy with ≥15 eos/HPF AND weight ≥15 kg AND symptoms of esophageal dysfunction AND trial/failure of PPI or swallowed topical steroid ≥2 months; reauth requires reduction in eosinophils or symptoms

    Prescriber specialist required.

    Dupixent — AD / chronic urticaria / BP etc.: Indication-specific documentation required (e.g., moderate-to-severe AD: trial/failure of medium/high potency topical steroid or calcineurin inhibitor; chronic urticaria >6 weeks: trial/failure of H1 antihistamine; bullous pemphigoid: trial/failure of oral/high-potency topical steroid AND one steroid-sparing agent)

    Reauthorization requires documented clinical benefit.

    Ebglyss — AD initial and reauthorization

    Covered when ALL of the following are met:

    Ebglyss for atopic dermatitis initial: Confirmation of moderate-to-severe AD AND trial and failure to Rinvoq AND trial and failure to Dupixent; must not be used in combination with other biologics or JAK inhibitors; prescriber specialist involvement requiredinitial: 1 year limited to 4 doses first month then 2 doses monthly; reauth 2 years

    Reauthorization requires positive clinical response and maintenance dosing details.

    Dupixent initial and reauthorization for chronic urticaria and bullous pemphigoid

    Covered when ALL of the following are met:

    Dupixent — chronic urticaria initial: Diagnosis of urticaria >6 weeks AND trial and failure of one H1 antihistamine

    Reauthorization requires clinical benefit compared to baseline.

    Bullous pemphigoid coverage

    Covered when ALL of the following are met:

    Bullous pemphigoid initial: Diagnosis of bullous pemphigoid AND trial and failure (intolerance or inability to improve) with an oral or high-potency topical steroid AND one steroid-sparing agent (doxycycline, methotrexate, mycophenolate, or azathioprine)

    Reauthorization requires documentation supporting reduction in blister formation and itching.

    Eltrombopag ITP criteria

    Covered when ALL of the following are met:

    Eltrombopag for ITP initial: Platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors; inadequate response or intolerance to steroids or IVIG; inadequate response or intolerance to rituximab or splenectomy; not used in combination with other maintenance ITP drugs or other TPO receptor agonists

    Reauthorization requires platelet count <400 x10^9/L and documentation of positive response.

    Emgality criteria

    Covered when ALL of the following are met:

    Emgality — migraine prevention: At least four migraine days per month required for prevention; reauth requires documentation of decreased migraine days

    Must not be used in combination with other CGRP antagonist therapy.

    Emgality — cluster headache: Trial of verapamil with intolerance or inability to improve required for cluster headache initial requests; reauth requires decreased frequency or intensity

    Dosing per FDA label.

    Enbrel condition-specific step requirements

    Covered when ALL of the following are met:

    Enbrel — RA: Trial and failure of one traditional non-biologic immunomodulator (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) required for RA; prescriber specialist or consultation required

    Dose per FDA label.

    Enbrel — AS: Trial and failure of one NSAID required for ankylosing spondylitis
    Enbrel — psoriasis: Trial and failure of one traditional non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) required for psoriasis

    EoE criteria

    Covered when ALL of the following are met:

    EoE initial: Diagnosis confirmed by esophageal biopsy with ≥15 eosinophils/HPF AND continued symptoms despite PPI trial ≥2 months AND trial of topical generic corticosteroid ≥2 months with ongoing symptoms; age ≥11 and prescriber specialist requiredauthorization 1 year with 12-week treatment limit

    Reauthorization requires positive response (reduced eosinophils or symptoms).

    Evrysdi criteria

    Covered when ALL of the following are met:

    Evrysdi (SMA) initial: Genetic test confirming SMA diagnosis AND patient not receiving concurrent Spinraza or prior/planned gene therapy (Zolgensma); prescribed by or in consultation with neurologist experienced in SMAinitial & reauth 12 months

    Reauthorization requires documentation of positive clinical response.

    Fasenra indications

    Covered when ALL of the following are met:

    Fasenra — severe eosinophilic asthma initial: Blood eosinophil count ≥150 cells/µL within 6 weeks prior to start OR ≥300 cells/µL in prior 12 months AND trial and failure of 1 ICS/LABA inhaler in past 6 months

    Reauthorization requires documentation of clinical benefit vs baseline; prescriber specialist required.

    Fasenra — EGPA initial: Documentation patient has non-severe EGPA (no life- or organ-threatening manifestations)

    Reauthorization requires documentation of clinical benefit.

    Growth hormone therapy criteria

    Covered when ALL of the following are met:

    Growth hormone — pediatric criteria: Submit untreated growth velocity curve ≥1 year showing growth velocity <10th percentile for bone age and gender; open growth plates; bone age ≥1 year behind chronological age (exceptions apply); documented GH deficiency via 2 GH stimulation tests <10 ng/mL OR GH stimulation <15 ng/mL plus low IGF-1 and IGFBP3; decreased muscle tone on exam

    Prescriber must be endocrinologist, gastroenterologist, or nephrologist; coverage duration 1 year.

    Growth hormone — adult criteria: Confirmation of GHD by one of: suboptimal response on appropriate GH-stimulation test; persistent childhood-onset GHD confirmed; OR documented pituitary/hypothalamic disease with ≥3 pituitary hormone deficiencies AND low IGF-1 (if indeterminate, require suboptimal stimulation test)

    Prescriber involvement as specified.

    Biologic therapy criteria — class-wide rules

    Covered when ALL of the following are met:

    Biologic agents — combination exclusion: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors for the treated condition

    Documentation of prior therapies and responses required; condition-specific step therapy before many biologics (try and fail traditional non-biologic immunomodulator for RA, etc.).

    Biologic agents — IBD shortened-interval dosing: For shortened-interval dosing approvals in Crohn's/UC require: (1) two of: symptoms, imaging showing active disease, fecal calprotectin >120, CRP ≥300; (2) inadequate trough levels; and (3) initial response to therapy

    Prescriber specialist required.

    HAE coverage criteria

    Covered when ALL of the following are met:

    HAE agents initial: Provide C4, C1-INH protein, and C1-INH function lab results confirming diagnosis; prescriber must be specialist experienced in HAE; concurrent ACE inhibitor use is not coveredcoverage duration 6 months

    Reauthorization requires decreased attack frequency or documentation of prior approved syringes and favorable clinical response as appropriate.

    IVIG criteria

    Covered when ALL of the following are met:

    IVIG dosing and indication: Provide current weight and requested dose; dosing must follow FDA labeling or accepted standards; weight-adjusted dosing if BMI ≥30 or actual weight ≥20% above ideal; provide supporting medical records. For myasthenia gravis: covered for acute myasthenic crisis with decompensation only; chronic/routine use in stable MG is not covered

    Reauthorization requires demonstrated clinical benefit where applicable.

    IDHIFA — mutation documentation

    Covered when ALL of the following are met:

    IDHIFA (enasidenib): Documentation of IDH2 mutation must be submittedcoverage duration 2 years

    Prescriber documentation required.

    Kerendia coverage criteria

    Covered when ALL of the following are met:

    Kerendia — HF (LVEF ≥40%) initial: NYHA class II–IV AND documented EF ≥40% within prior 12 months AND pre-treatment eGFR ≥25 mL/min/1.73 m2 AND prescribed by or in consultation with a cardiologist AND patient receiving at least two standard HF medications from different classes at appropriate dosescoverage duration 2 years

    CKD with T2DM requests require prior SGLT2i or GLP-1 RA trial or documented rationale for switching; must be on maximally tolerated ACEI or ARB.

    Levetiracetam formulation criteria

    Covered when ALL of the following are met:

    Levetiracetam disintegrating/soluble tablet criteria: Documentation of inability to use generic levetiracetam tablet AND trial and failure with one other generic anticonvulsant (failure = inability to improve condition)coverage duration 2 years

    Prescriber documentation required.

    Livtencity criteria

    Covered when ALL of the following are met:

    Livtencity initial: Baseline CMV DNA level confirming diagnosis AND documented trial and failure with ganciclovir, valganciclovir, cidofovir or foscarnet; dosing per FDA labeling; must not be used concomitantly with other CMV antiviralsinitial coverage 8 weeks

    Reauthorization requires documentation of response (e.g., CMV DNA level).

    Nexletol/Nexlizet criteria

    Covered when ALL of the following are met:

    Nexletol / Nexlizet eligibility: Submit most recent LDL-C AND either: trial of a high-intensity statin plus ezetimibe ≥4 weeks with LDL-C ≥70 mg/dL OR trial of ezetimibe ≥4 weeks with documented statin intolerance (≥2 statins with statin-related symptoms); must not be used with PCSK9 inhibitors or JuxtapidLDL-C >= 70 mg/dL

    Coverage duration 2 years.

    NURTEC criteria

    Covered when ALL of the following are met:

    NURTEC — prevention: For episodic migraine prevention initial requests: patient must have ≥4 and <15 migraine days per month4–14 migraine days/month

    Initial and reauth duration 1 year; reauth requires decreased migraine days.

    NURTEC — acute use: For acute migraine: unless contraindicated, trial and failure of one generic triptan required

    Prescriber documentation required.

    Nulibry criteria

    Covered when ALL of the following are met:

    Nulibry initial: Confirmed diagnosis of MoCD Type A by genetic testing (submit results); prescriber specialization requiredinitial 1 year; reauth 2 years

    Reauthorization requires documentation of beneficial response in neurological or developmental measures.

    Representative initial coverage rules

    Representative initial coverage rules (examples) — covered when ALL of the following relevant criteria are met:

    Pirfenidone / Nintedanib-class (IPF): Diagnosis confirmed by surgical lung biopsy OR UIP pattern on HRCT; prescriber must rule out other causes of ILD; HRCT documentation required; FVC decline criteria apply for progressive fibrosing ILD

    Reauthorization requires documentation of improvement or stabilization.

    Radicava initial: Definite or probable ALS per revised El Escorial criteria, diagnosis ≤2 years, baseline ALSFRS‑R ≥24, %FVC ≥80% predicted; reauth requires evidence Radicava is slowing progressionALSFRS‑R ≥24; %FVC ≥80%

    Prescriber documentation required.

    Rezdiffra initial therapy

    Rezdiffra initial authorization — covered when ALL of the following are met:

    Rezdiffra initial: Diagnosis of MASH AND moderate–advanced liver fibrosis consistent with F2 or F3 confirmed by biopsy or NITs AND current weight provided AND Rezdiffra dose aligned with FDA labeling (80 mg/day if weight <100 kg; 100 mg/day if weight ≥100 kg) AND provider attestation Rezdiffra will be used with diet and exercisedose by weight per FDA

    Policy source text indicates additional 'trial and failure with' requirement (excerpt truncated). Prescriber must be gastroenterologist or hepatologist.

    Rezdiffra reauthorization

    Rezdiffra reauthorization — covered when ALL of the following are met:

    Rezdiffra reauthorization: Current ALT and/or fibrosis score showing no worsening (no consistent ALT increase or fibrosis progression by biopsy/NITs) AND current weight AND dose aligned with FDA labeling (80 mg/day if weight <100 kg; 100 mg/day if weight ≥100 kg) AND provider attestation of ongoing use with diet and exercise

    Reauthorization duration one year.

    Biologic initial therapy — class and product examples

    Covered when ALL of the following are met:

    Biologic initial therapy (e.g., Romvimza, other biologics): Documentation of prior therapies and responses required; prescriber must be a specialist or have consulted one; dose supported by FDA label or compendia; disease-specific step therapy requirements apply (e.g., RA: failure of one traditional non-biologic immunomodulator)initial durations vary by indication (commonly 1–2 years)

    Combination with other biologics, Otezla, or JAK inhibitors for same condition is prohibited.

    Sodium oxybate criteria

    Covered when ALL of the following are met:

    Sodium oxybate (narcolepsy) initial: Documentation of prior therapies (stimulants and modafinil/armodafinil) with intolerance or failure AND MSLT and polysomnography confirming narcolepsy; prescriber must be sleep specialist or neurologistcoverage duration 2 years

    Reauthorization requires documentation of decreased daytime sleepiness or cataplexy.

    Tavneos initial and reauthorization

    Covered when ALL of the following are met:

    Tavneos initial: Patient ≥18 AND prescribed by or in consultation with specialist AND used as add‑on to standard therapy (e.g., cyclophosphamide, rituximab, steroids) AND patient not currently requiring dialysisinitial 6 months; reauth 12 months

    Reauthorization requires reduction in BVAS and steroid dose.

    Teriparatide coverage

    Covered when ALL of the following are met:

    Teriparatide prerequisites: Either trial/failure/intolerance/contraindication to oral bisphosphonates (alendronate, risedronate, ibandronate) AND zoledronic acid, OR very high fracture risk defined as T‑score ≤‑3.0 OR T‑score ≤‑2.5 with fragility fracture OR history of severe/multiple fragility fractures

    Prescriber must be an endocrinologist; coverage two years.

    Testosterone therapy criteria

    Covered when ALL of the following are met:

    Testosterone therapy for hypogonadism: Two pre‑treatment morning serum total testosterone levels on separate days <300 ng/dL (or low per lab reference) AND pre‑treatment clinical signs/symptoms of low testosterone other than erectile dysfunction and decreased libido (examples: depressed mood, decreased energy, progressive loss of muscle mass, osteoporosis)testosterone <300 ng/dL

    Coverage duration two years; prescriber documentation required.

    Testosterone (topical/transdermal solution) — Initial coverage

    Covered when ALL of the following are met:

    Testosterone (topical/transdermal solution) — initial: Two pre‑treatment morning serum total testosterone levels on separate days <300 ng/dL OR low per lab reference AND pre‑treatment clinical signs/symptoms of low testosterone other than erectile dysfunction and decreased libido (examples provided)total testosterone <300 ng/dL

    Coverage duration two years.

    tolvaptan — Indication-specific criteria

    Covered when ONE of the following indication-specific branches is met:

    Tolvalptan — hyponatremia: Documentation confirming hypervolemic or euvolemic hyponatremia defined as serum sodium <125 mEq/L OR symptomatic nonresponsive to fluid restriction (including SIADH or heart failure); tolvaptan used up to 60 mg/day per FDA labelingserum sodium <125 mEq/L

    Coverage duration for hyponatremia: 30 days.

    Tolvalptan — ADPKD: Patient at risk of rapidly progressing ADPKD AND tolvaptan used up to 120 mg/day per FDA labelingper FDA dosing

    Coverage duration for ADPKD: 2 years.

    tetrabenazine — safety and documentation

    Covered when ALL of the following are met:

    Tetrabenazine safety and documentation: Must not be used in combination with deutetrabenazine (Austedo) or valbenazine (Ingrezza); CYP2D6 genotype must be provided for doses >50 mg/dayCYP2D6 genotype for >50 mg/day

    Coverage duration two years.

    TYENNE SUBCUTANEOUS — initial and reauthorization

    Covered when ALL of the following are met:

    Tyenna (and related biologic) initial: Must not be used in combination with other biologic drugs, Otezla, JAK inhibitors, or Ofev; documentation of prior therapies and responses required; for SSc‑ILD HRCT confirming diagnosis requiredcoverage duration 2 years

    Prescriber must be a specialist or have consulted one; reauthorization requires improvement for SSc‑ILD.

    VOYDEYA — PNH criteria

    Covered when ALL of the following are met:

    Voydeya — PNH initial: Diagnosis of PNH confirmed by flow cytometry AND actively receiving ravulizumab or eculizumab AND symptomatic extravascular hemolysis defined by fatigue or dyspnea AND Hgb <9.5 g/dL OR absolute reticulocyte count >120 x10^9/LHgb <9.5 g/dL or ARC >120 x10^9/L

    Initial and reauth duration one year; reauthorization requires improvement in EVH symptoms and lab markers.

    VYNDAMAX — ATTR-CM criteria

    Covered when ALL of the following are met:

    Vyndamax — ATTR‑CM initial: NYHA class I–III AND ECHO or CMR demonstrating cardiac involvement (increased LV wall thickness) AND diagnosis confirmed by biopsy, genetic testing, or radionuclide imaging (Grade 2–3 uptake if imaging used); not approved for primary light‑chain amyloidosisNYHA I–III

    Initial coverage one year; reauthorization requires clinical response vs baseline.

    Winrevair Initial Therapy

    Covered when ALL of the following are met:

    Winrevair initial (PAH): Right heart catheterization confirming WHO Group 1 PAH AND WHO functional class II or III AND trial and failure of dual therapy with a PDE5 inhibitor AND an endothelin receptor antagonist AND Winrevair will be initiated as add‑on therapyage ≥18

    Prescribed by or in consultation with a specialist; initial one year, reauth two years requiring demonstrated benefit (WHO class, risk status, or 6MWD).

    Xolair Initial Therapy

    Covered when ALL of the following are met (indication-specific):

    Xolair — asthma initial: Baseline IgE ≥30 IU/mL AND baseline positive skin or in vitro reactivity to a perennial aeroallergen AND patient's current weight AND trial and failure of 1 ICS/LABA in past 6 monthsbaseline IgE >=30 IU/mL

    Prescriber specialist required; initial 1 year, reauth 2 years; reauth requires documentation of clinical benefit and current weight/IgE.

    Xolair — food allergy initial: IgE‑mediated food allergy confirmed by positive in vitro IgE AND positive skin prick AND clinical history of significant allergic reaction AND baseline IgE ≥30 IU/mL AND use with allergen-avoidant diet AND patient's weight AND age ≥1 yearage ≥1 year; baseline IgE >=30 IU/mL

    Reauth requires continued diet use and documentation of benefit.

    Xolair — chronic urticaria initial: Chronic urticaria >6 weeks AND trial and failure of one H1 antihistamine

    Reauthorization requires clinical benefit documented.

    Xolair — nasal polyps initial: Baseline IgE ≥30 IU/mL AND patient's current weight AND trial and failure of intranasal steroid AND continued intranasal steroid use with Xolair

    Reauthorization requires clinical benefit and continued intranasal steroid use.

    Xifaxan Coverage Limits

    Coverage limits and exclusions:

    Xifaxan limits: For IBS‑D: coverage limited to no more than three 14‑day treatment courses; SIBO is not covered. For traveler’s diarrhea: trial and failure with azithromycin required and TD limited to three days. For hepatic encephalopathy: trial and failure with lactulose requiredIBS‑D ≤ 3 courses; TD ≤ 3 days

    Prescriber documentation of prior trials required.

    Yorvipath Initial Therapy

    Covered when ALL of the following are met:

    Yorvipath initial for chronic hypoparathyroidism: Confirmed chronic hypoparathyroidism ≥6 months with labs drawn together (serum PTH, calcium, magnesium, phosphate) AND provider attestation that calcium and vitamin D therapy is inadequate AND age ≥18 AND prescribed by or in consultation with an endocrinologistage ≥18

    Initial and reauth duration one year; reauth requires improved serum calcium.

    Ztalmy Initial Therapy

    Covered when ALL of the following are met:

    Ztalmy initial (CDKL5 deficiency): Confirmation of CDKL5 deficiency by genetic testing AND patient's current weight AND age ≥2 years AND prescribed by a neurologistage ≥2

    Coverage duration two years.

    Biologic/JAKi Combination and Prior Therapy Requirements

    Covered when ALL of the following are met (class-wide biologic/JAKi rules):

    Biologic/JAKi combination and prior therapy requirements: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors for the same condition; documentation of prior therapies and responses required; prescriber is a specialist or has consulted one; indication-specific prior therapy trials (e.g., RA: failure of one traditional non-biologic immunomodulator) applycoverage durations typically 1–2 years

    Failure defined as intolerance or inability to improve the condition; reauthorization requires demonstrated clinical benefit.

    Examples of indications expressly excluded for ACTHAR are listed in the policy. ACTHAR is not covered for acute gouty arthritis, severe psoriasis, and atopic dermatitis. (For covered ACTHAR indications, the policy requires documentation of prior therapies and a therapeutic trial of a parenteral glucocorticoid and Cortrophin for all indications except infantile spasms, with quantity limited to FDA-supported dosing and reauthorization requiring demonstrated clinical benefit.)

    The policy enforces a class-wide prohibition on combining adalimumab-class and other listed biologic agents with other biologic drugs, Otezla (apremilast), or Janus kinase inhibitors (JAKis). Requests that show concomitant use of these agents for the same condition risk denial; documentation must show prior therapy trials and that the agent will not be administered in combination with excluded therapies.

    This same combination prohibition is applied consistently across several biologic product entries (for example, Cosentyx, Dupixent, Ebglyss and other anti‑inflammatory biologics) and is reiterated in the biologics and JAKi coverage sections of the policy; prescribers must follow indication‑specific step/ prior‑therapy requirements and attest no excluded concurrent biologic/JAKi or Otezla use.

    Amvuttra is restricted to transthyretin (TTR)-mediated indications and the policy explicitly excludes use in patients with primary (light‑chain) amyloidosis. Initial coverage for HATTR‑PN and ATTR‑CM requires diagnostic confirmation (including genetic testing) and condition‑specific documentation (e.g., baseline PND score ≤ IIIb for HATTR‑PN; tafamidis failure/intolerance and cardiac imaging/NYHA class for ATTR‑CM). Requests for primary (light‑chain) amyloidosis will not be approved.

    The policy excludes nebulized or inhalation administration of colistimethate. Coverage is limited to intravenous (IV) or intramuscular (IM) use only and requires documentation that the infection is proven or strongly suspected to be caused by susceptible organisms (culture and susceptibility or supporting local epidemiology); infectious disease specialist prescribing or consultation is required.

    The document provides multiple examples of biologic/JAK inhibitor combination prohibitions. Specific biologic products (for example, Cosentyx, Dupixent, Ebglyss and other listed biologics) state they must not be used in combination with other biologic drugs or JAK inhibitors for the same condition. Such combination use is an explicit exclusion and may be a basis for denial if documented in a request.

    Providers must therefore document prior therapy trials and that the requested biologic will be used alone (or per permitted sequencing) — the policy repeatedly cites this combination prohibition and treats concurrent biologic + JAKi (or biologic + biologic, or biologic + Otezla where stated) as a disqualifying scenario.

    Summary: the policy applies product- and class-wide combination restrictions for many biologic and immunomodulatory agents. In practice this means the requested biologic cannot be co‑prescribed with other biologics, Otezla, or JAK inhibitors for the same condition unless the product entry explicitly permits it. These product combination restrictions are reiterated throughout the biologics and JAKi sections and are enforced during prior authorization review.

    Coding and Measurable Thresholds

    Document identifiermixed
    337Page or internal identifier shown on document
    Products listed (no explicit billing codes in this segment)mixed
    N/AProduct list includes many NDC/brand entries; no explicit CPT/HCPCS/ICD-10 codes listed in this segment.
    Products listed (sample)mixed
    KISQALI FEMARA (200 MG DOSE)listed product entry
    KISQALI FEMARA (400 MG DOSE)listed product entry
    KISQALI FEMARA (600 MG DOSE)listed product entry
    Levetiracetam formulationsmixed
    levetiracetam oral tablet disintegrating soluble 250 mg, 500 mgformulation-specific product entry
    Livtencitymixed
    LIVTENCITYproduct entry
    Nexletol CPT/HCPCS entriesmixed
    NEXLETOLproduct entry
    Nexlizet CPT/HCPCS entriesmixed
    NEXLIZETproduct entry
    NURTECmixed
    NURTECproduct entry
    Products listed (alphabetical O-R segment)mixed
    No codes listed
    Laboratory thresholdsmixed
    300 ng/dLtestosterone threshold referenced for hypogonadism
    Index entries (no explicit CPT/HCPCS/ICD codes in these chunks)mixed
    No codes listed
    Fecal calprotectin threshold (inv-110)
    Fecal calprotectin threshold> 120
    Context of useUsed as objective evidence for shortened-interval dosing approvals in Crohn’s disease and ulcerative colitis
    Documentation requirementMust be provided as part of prior therapy and objective disease documentation when applicable
    CRP threshold (inv-111)
    CRP threshold (policy units)>= 300
    Context of useUsed with symptoms/imaging and fecal calprotectin as objective evidence for shortened-interval dosing in IBD
    Documentation requirementSubmit result as part of prior therapy and objective disease documentation when requesting shortened-interval dosing
    Baseline PND score threshold for HATTR-PN (inv-112)
    Baseline PND score requirementLess than or equal to IIIb
    IndicationRequired for Amvuttra initial coverage for HATTR-PN
    Other required diagnostic evidenceGenetic confirmation of TTR mutation and clinical signs/symptoms of neuropathy
    Blood eosinophil count threshold for Fasenra (inv-113)
    Blood eosinophil count (initial Fasenra)>= 150 cells/μL within 6 weeks OR >= 300 cells/μL in prior 12 months
    Additional requirementTrial and failure of 1 ICS/LABA inhaler in past 6 months
    PrescriberPrescriber is a specialist or has consulted with a specialist
    EOE biopsy eosinophil count threshold (inv-114)
    EOE biopsy eosinophil threshold>= 15 eosinophils per high power field (HPF)
    Additional criteriaPersistent symptoms despite >=2 months PPI and trial of topical steroid >=2 months
    Age requirementMust be age 11 years or older
    Pediatric growth velocity for GH therapy (inv-115)
    Pediatric growth velocity requirementGrowth velocity < 10th percentile for bone age and gender with >=1 year of growth data
    Bone ageBone age at least 1 year behind chronological age (exceptions for GHD related to pituitary surgery/radiation/precocious puberty)
    GH deficiency confirmationDocumented GH deficiency via two GH stimulation tests <10 ng/mL or alternative criteria with IGF-1/IGFBP3
    GH stimulation test threshold (inv-116)
    GH stimulation test suboptimal responseBelow 10 ng/mL (or <15 ng/mL plus supportive low IGF-1/IGFBP3 findings)
    Alternative confirmationChild-onset persistent GHD or pituitary/hypothalamic disease with >=3 pituitary hormone deficits and low IGF-1
    Use in adultsSuboptimal response on appropriate GH-stimulation test required for adult GHD confirmation
    Eltrombopag reauthorization platelet count threshold (inv-117)
    Eltrombopag reauthorization platelet countCurrent platelet count < 400 x 10^9/L
    Reauthorization evidenceDocumentation supporting positive response to therapy required
    Initial platelet thresholdsDifferent initial thresholds apply by indication (see initial ITP criteria)
    ITP platelet threshold for initial eltrombopag (inv-118)
    ITP platelet threshold (initial)Platelet count < 30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors
    Prerequisite therapiesInadequate response or intolerance to steroids/IVIG AND to rituximab or splenectomy required
    Combination exclusionMust not be used with other maintenance ITP drugs including other TPO receptor agonists
    Fecal calprotectin (repeat key) (inv-119)
    Fecal calprotectin threshold (repeat)> 120
    ContextUsed as one of two objective measures for shortened-interval dosing approvals in Crohn’s/UC
    DocumentationMust be included with prior therapy and objective disease documentation when applicable
    CRP (repeat key) (inv-120)
    CRP threshold (repeat)>= 300
    ContextUsed with symptoms/imaging and fecal calprotectin for shortened-interval dosing in IBD
    DocumentationSubmit CRP result as part of objective disease documentation when requesting therapy changes
    Migraine days per month (NURTEC prevention) (inv-121)
    Migraine days per month (NURTEC prevention)≥4 and <15 migraine days/month
    Coverage durationInitial and reauthorization durations: 1 year; reauth requires decrease in migraine days
    Acute use requirementAcute NURTEC requires prior trial/failure of a generic triptan unless contraindicated
    LDL-C threshold for Nexletol/Nexlizet eligibility (inv-122)
    LDL-C threshold for Nexletol/Nexlizet≥ 70 mg/dL
    Prior therapy requirementTrial of high-intensity statin + ezetimibe >=4 weeks, or ezetimibe >=4 weeks with documented statin intolerance
    Combination exclusionMust not be used with PCSK9 inhibitors (e.g., Repatha) or Juxtapid
    Radicava ALSFRS-R baseline requirement (inv-123)
    Radicava ALSFRS-R baseline requirementMinimum total score 24 (at least 2 points on each of 12 items)
    %FVC requirementPercent-predicted FVC >= 80%
    Timing and diagnosisDiagnosis definite/probable ALS by revised El Escorial/Arlie House criteria and diagnosis within 2 years
    %FVC threshold for Radicava initial eligibility (inv-124)
    %FVC threshold for Radicava initial eligibility≥ 80% predicted
    Associated ALSFRS-R requirementBaseline ALSFRS-R minimum total score 24 required
    Reauthorization evidenceDocumentation that Radicava is slowing ALS progression required for reauth
    AAT serum level for augmentation therapy (inv-125)
    Alpha-1 antitrypsin (AAT) serum level thresholdLess than 11 micromoles per liter (80 mg/dL by radial immunodiffusion or 50 mg/dL nephelometry)
    Associated pulmonary function requirementFEV1 < 80% predicted required for augmentation therapy
    IndicationRequired for Prolastin-C augmentation therapy eligibility
    Rezdiffra dosing by weight (inv-126)
    Rezdiffra dosing by weight80 mg/day if weight < 100 kg; 100 mg/day if weight ≥ 100 kg
    Provider attestationTherapy must be used in conjunction with diet and exercise per FDA labeling
    Diagnostic requirementMASH with fibrosis stage F2 or F3 confirmed by biopsy or NITs required for initial authorization
    Tetrabenazine genotype requirement (inv-127)
    Tetrabenazine genotype requirementCYP2D6 genotype must be provided for doses > 50 mg/day
    Combination exclusionMust not be used in combination with Austedo (deutetrabenazine) or Ingrezza (valbenazine)
    Coverage durationTwo years
    Testosterone lab threshold — two morning totals <300 ng/dL (inv-128)
    Testosterone laboratory thresholdTwo morning total testosterone levels, each < 300 ng/dL
    Clinical requirementPre-treatment signs/symptoms of low testosterone other than erectile dysfunction and decreased libido required
    Coverage durationTwo years
    Very high fracture risk (teriparatide) — T-score thresholds (inv-129)
    Very high fracture risk — T-score thresholdsT-score <= -3.0 OR T-score <= -2.5 with a fragility fracture
    Alternative eligibilityHistory of severe or multiple fragility fractures regardless of T-score qualifies
    PrescriberMust be prescribed by an endocrinologist
    Serum sodium threshold for tolvaptan hyponatremia use (inv-130)
    Serum sodium threshold for tolvaptan (hyponatremia)< 125 mEq/L
    Indication-specific dosing limitsUp to 60 mg/day for hyponatremia; up to 120 mg/day for ADPKD as per FDA labeling
    Other criteriaDocument hypervolemic or euvolemic hyponatremia and nonresponse to fluid restriction when applicable
    Total testosterone reference (repeat) (inv-131)
    Total testosterone reference< 300 ng/dL
    Measurement timingTwo pre-treatment morning measurements on separate days required for diagnosis
    Clinical correlationMust document clinical signs/symptoms of hypogonadism beyond erectile dysfunction/decreased libido
    Hemoglobin threshold for Voydeya EVH (inv-132)
    Hemoglobin threshold for Voydeya (EVH)< 9.5 g/dL
    Additional EVH criteriaPNH confirmed by flow cytometry and active treatment with ravulizumab or eculizumab required
    Reauthorization evidenceDocumented improvement in EVH symptoms and lab markers required
    Baseline IgE requirement for Xolair (inv-133)
    Baseline IgE requirement for Xolair>= 30 IU/mL
    Baseline definedBaseline = before treatment with Xolair or another therapy that lowers IgE levels
    Additional requirementPositive skin or in vitro reactivity to a perennial aeroallergen (for asthma) and patient weight must be provided
    Xifaxan IBS-D course limit (inv-134)
    Xifaxan IBS-D course limitNo more than three 14-day treatment courses
    Traveler's diarrhea (TD) duration limitTD limited to three days; requires trial/failure with azithromycin
    SIBO coverage stanceCoverage for SIBO is not provided (explicit exclusion)
    Xifaxan TD duration limit (inv-135)
    Xifaxan TD duration limitThree days
    Prerequisite for TDTrial and failure with azithromycin required for traveler’s diarrhea
    IBS-D limitIBS-D limited to up to three 14-day courses

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    General prior authorization and duration

    Submit a prior authorization for specialty products and include documentation of prior therapies and responses; quantity/dosing must follow FDA labeling and reauthorization generally requires demonstrated clinical benefit (durations vary by product).

    • Prior authorization required for listed specialty products.
    • Provide documentation of prior therapies and responses to treatment.
    • Quantity/dosing limited to FDA-approved label; reauthorization requires evidence of clinical benefit; typical durations 1–2 years.
    Prior Authorization

    Aimovig prior authorization

    For Aimovig initial migraine prevention requests, prior authorization requires documentation of at least four migraine days per month; initial approval is 1 year and reauthorization requires documentation of decreased migraine days (reauth 2 years in some entries).

    • Must document ≥4 migraine days per month for prevention.
    • Dosing must align with FDA labeling.
    • Initial authorization: 1 year; reauthorization requires decreased migraine days per month.
    Prior Authorization

    Prior authorization requirement for listed products

    Submit a prior authorization for each listed product in the index portion of the policy and include the product-specific required documentation (diagnosis confirmation, prior trial/failure documentation, prescriber specialty) as specified in each product entry.

    • Prior authorization required for the listed products; follow each product’s criteria.
    • Typical coverage durations are one or two years depending on product.
    Prior Authorization

    Initial prior authorization requirements

    For initial authorization requests, include documentation of the diagnosis and evidence of prior therapy failure or intolerance as specified by the product (examples: chronic urticaria >6 weeks plus H1 antihistamine failure; bullous pemphigoid with steroid and steroid‑sparing agent trial).

    • Provide diagnosis confirmation per product rules.
    • Document prior trial(s) and reason for failure/intolerance as defined by the policy.
    Prior Authorization

    Atopic dermatitis prior authorization

    For atopic dermatitis products that require it, prior authorization must document moderate‑to‑severe disease and trial/failure of Rinvoq and Dupixent before approval of the specified agent.

    • Confirm moderate-to-severe atopic dermatitis.
    • Document trial and inadequate response or intolerance to Rinvoq and Dupixent.
    Prior Authorization

    Prior authorization required

    Many specialty products require prior authorization; submit indication‑specific documentation and note that coverage durations vary (commonly 1–2 years).

    • Follow product-specific criteria for labs, trials, and prescriber restrictions.
    • Expect initial approvals commonly 1–2 years with reauthorization requirements.
    Prior Authorization

    Prior auth for HAE agents

    Prior authorization for hereditary angioedema (HAE) agents (e.g., icatibant) requires submission of diagnostic labs (C4, C1‑INH protein, C1‑INH function) and that the prescriber be a specialist experienced in HAE.

    • Submit C4, C1‑INH protein, and C1‑INH function lab results confirming diagnosis.
    • Prescriber must be an allergist/immunologist/hematologist or other HAE‑experienced specialist.
    Prior Authorization

    KISQALI FEMARA PA requirement

    KISQALI FEMARA entries require prior authorization; coverage duration is two years and indications are the medically‑accepted or FDA‑approved indications listed in the policy.

    • Submit PA for KISQALI FEMARA formulations.
    • Coverage duration: two years; indications: medically‑accepted/FDA‑approved per entry.
    Prior Authorization

    Levetiracetam disintegrating tablet PA

    Levetiracetam disintegrating/soluble tablet formulations require prior authorization documenting inability to use the generic tablet and a trial and failure of one other generic anticonvulsant.

    • Document why the standard generic levetiracetam tablet cannot be used (e.g., dysphagia).
    • Provide records showing trial and inadequate response or intolerance to one other generic anticonvulsant.
    Prior Authorization

    Livtencity PA and sequencing

    For Livtencity, submit a prior authorization with baseline CMV DNA confirming diagnosis, documentation of prior trial/failure with listed antivirals, and note Livtencity must not be used concomitantly with other CMV antivirals; initial coverage duration is 8 weeks and reauthorization requires evidence of response (e.g., CMV DNA).

    • Provide baseline CMV DNA level confirming active infection.
    • Document trial and failure with ganciclovir, valganciclovir, cidofovir, or foscarnet.
    • Do not use concurrently with other CMV antivirals; initial coverage 8 weeks.
    Prior Authorization

    Nexletol PA criteria

    Nexletol prior authorization requires submission of the most recent LDL‑C and documentation of prior therapy: trial of a high‑intensity statin plus ezetimibe for ≥4 weeks with LDL‑C ≥70 mg/dL, or documented statin intolerance; coverage duration typically two years.

    • Submit most recent LDL‑C level (policy threshold ≥70 mg/dL).
    • Document trial of high‑intensity statin + ezetimibe ≥4 weeks OR statin intolerance (≥2 statins with symptoms).
    Prior Authorization

    Nexlizet PA criteria

    Nexlizet prior authorization mirrors Nexletol: submit LDL‑C and prior statin/ezetimibe trial documentation or statin intolerance; Nexlizet must not be used with PCSK9 inhibitors or Juxtapid; coverage duration commonly two years.

    • Submit most recent LDL‑C and prior therapy documentation as for Nexletol.
    • Do not combine with PCSK9 inhibitors (e.g., Repatha) or Juxtapid.
    Prior Authorization

    Nurtec PA requirements

    Nurtec prior authorization is required for both episodic prevention and acute use: prevention initial requests require 4–14 migraine days per month; acute use requires trial/failure of a generic triptan unless contraindicated; initial and reauthorization durations are typically 1 year.

    • Episodic prevention: document 4–14 migraine days/month.
    • Acute use: document trial and failure of a generic triptan unless contraindicated.
    • Initial/reauthorization duration: 1 year.
    Prior Authorization

    Prior authorization required for listed products

    Many listed specialty products require prior authorization with product‑specific documentation (diagnostic confirmation, prior therapy trials, prescriber specialty); follow each product’s criteria when submitting PA requests.

    • Review the product entry for required labs, trials, and prescriber qualifications.
    • Expect initial approvals commonly 1–2 years with reauthorization requirements.
    Prior Authorization

    Rezdiffra prior authorization

    Rezdiffra prior authorization requires documentation of MASH diagnosis with fibrosis stage F2–F3 (by biopsy or NITs), current weight and FDA‑aligned dosing (80 mg/day if <100 kg; 100 mg/day if ≥100 kg), and provider attestation that therapy will be used with diet and exercise.

    • Provide evidence of MASH and fibrosis stage F2–F3 (biopsy or NITs).
    • Submit current weight and confirm dosing per FDA (80 mg/day if <100 kg; 100 mg/day if ≥100 kg).
    • Include attestation that diet and exercise accompany therapy.
    Prior Authorization

    Biologics prior authorization

    Many biologic agents require prior authorization that includes documentation of prior therapies, specialist prescribing or consultation, and adherence to combination‑use prohibitions (no concurrent use with other biologics, Otezla, or JAK inhibitors where stated).

    • Provide prior therapy history and reasons for failure/intolerance.
    • Prescriber should be a specialist or document specialist consultation.
    • Do not combine with other biologics, Otezla, or JAK inhibitors when policy excludes combination use.
    Prior Authorization

    Product-specific prior authorization required

    Many products require product‑specific prior authorization—include indication‑specific labs, diagnostic confirmation, and prior treatment trials as listed in each product entry.

    • Follow each product’s required lab or diagnostic submissions (e.g., IDH2 for IDHIFA, baseline CMV DNA for Livtencity).
    • Provide prior therapy trial documentation as required.
    Prior Authorization

    Winrevair PA requirement

    Winrevair prior authorization requires right heart catheterization confirming WHO Group 1 PAH, WHO functional class II–III, documentation of prior failure of dual PDE5 inhibitor + endothelin receptor antagonist therapy, and that Winrevair will be initiated as add‑on therapy; initial coverage is one year.

    • Submit RHC confirming PAH (WHO Group 1) and WHO FC II–III.
    • Document failure of dual therapy with a PDE5 inhibitor and an endothelin receptor antagonist.
    • Confirm Winrevair will be added to current regimen; initial coverage: 1 year.
    Prior Authorization

    Xolair PA requirement

    Xolair prior authorization requires baseline testing (IgE ≥30 IU/mL and allergen reactivity for asthma where applicable), patient weight, trial/failure of indicated prior therapies (e.g., ICS/LABA for asthma), specialist prescriber or consultation, and initial authorization is typically one year with reauthorization requirements for documented benefit.

    • Provide baseline IgE ≥30 IU/mL (baseline = before IgE‑lowering therapy) and allergen testing as applicable.
    • Submit patient weight and documentation of prior therapy trials/failures.
    • Prescriber must be or consult a specialist; initial 1 year, reauth typically 2 years with evidence of benefit.
    Prior Authorization

    Xifaxan PA requirement

    Xifaxan prior authorization excludes coverage for SIBO and limits IBS‑D to no more than three 14‑day courses; traveler’s diarrhea is limited to three days and requires prior trial/failure with azithromycin for TD, and hepatic encephalopathy requires trial/failure with lactulose.

    • SIBO: not covered (explicit exclusion).
    • IBS‑D: coverage limited to ≤3 total 14‑day courses.
    • Traveler’s diarrhea: coverage ≤3 days and requires prior azithromycin trial/failure.
    • Hepatic encephalopathy: requires prior lactulose trial/failure.
    Note

    Index — drug/product listings

    The product/index listings in the policy are for reference; the index sections list products and formulations but do not themselves state specific prior authorization rules or billing codes—use the product entries elsewhere in the policy for PA actions.

    • Index entries list product names/formulations and page references.
    • Index sections do not constitute PA rules—submit PA per product criteria.
    Note

    Index — no PA rules

    Do not rely on the index alone for PA rules: this index section does not contain explicit prior authorization requirements or affected billing codes; use the product criteria sections for action.

    • Index-only pages do not state prior authorization triggers.
    • Refer to individual product entries for PA requirements.
    Step Therapy

    Product-specific prerequisite therapy

    Some products require specific prerequisite therapies before authorization (example: ACTHAR and Cortrophin often require a prior trial of a parenteral glucocorticoid; follow each product entry for the exact required prior therapy).

    • Include documentation of prerequisite therapy trials (parenteral glucocorticoid for ACTHAR/Cortrophin except infantile spasms).
    • Supporting documentation must show inadequate response, intolerance, or contraindication.
    Step Therapy

    Auvelity step therapy

    Auvelity requires prior failure of an SSRI or SNRI and one atypical antidepressant (e.g., bupropion, mirtazapine); trials are defined as at least 4 weeks and must be documented when submitting PA.

    • Document trials of an SSRI or SNRI and one atypical antidepressant with dates and outcomes.
    • Failure defined as inability to improve depressive symptoms after ≥4 weeks.
    Step Therapy

    Step therapy requirements

    Many products impose step therapy: before requesting a PA, document completion and failure/intolerance of the specified prior trials (examples include topical steroid + calcipotriene for calcipotriene‑betameth suspension; non‑oral triptan and Nurtec for dihydroergotamine nasal; Rinvoq and Dupixent for Ebglyss).

    • Provide evidence of required step trials and reason for failure/intolerance.
    • Follow product‑specific trial durations where stated (e.g., 2 months for topical trials, 4 weeks for inhaler trials).
    Step Therapy

    Enbrel step therapy

    Enbrel prior authorization requires a trial and failure of one traditional non‑biologic immunomodulator for RA (e.g., methotrexate); document the trial and outcome when submitting PA.

    • Document trial and inadequate response or intolerance to a traditional non‑biologic immunomodulator.
    • Prescriber should be a specialist or document specialist consultation.
    Step Therapy

    Fasenra step therapy

    Fasenra prior authorization requires a blood eosinophil count meeting the policy threshold (≥150 cells/µL within 6 weeks OR ≥300 cells/µL in prior 12 months) and a trial/failure of an ICS/LABA inhaler within the past 6 months; include labs and prior therapy documentation in the PA.

    • Submit blood eosinophil count per threshold.
    • Document trial and failure of one ICS/LABA within past 6 months.
    Step Therapy

    Step therapy/failure requirements

    Biologic agents commonly require step therapy and prior treatment failures (e.g., traditional non‑biologic immunomodulators for psoriasis/RA); document the required prior trials and outcomes to support PA.

    • Provide prior‑therapy history showing trial and failure or intolerance.
    • Ensure documentation meets condition‑specific step requirements in the product entry.
    Step Therapy

    Levetiracetam step therapy

    Levetiracetam disintegrating/soluble tablets require documentation of trial and failure with one other generic anticonvulsant before approval; include medical records showing the trial and outcome.

    • Document the prior anticonvulsant trial (agent, dates, dose) and reason for failure/intolerance.
    • Include rationale why standard generic tablet cannot be used.
    Step Therapy

    Nexletol/Nexlizet step requirement

    Nexletol and Nexlizet step‑therapy requirement: document trial of a high‑intensity statin plus ezetimibe for ≥4 weeks with LDL‑C ≥70 mg/dL OR trial of ezetimibe ≥4 weeks with documented statin intolerance (attempt of ≥2 statins with symptoms).

    • Submit LDL‑C and dates/outcomes of statin + ezetimibe trial or ezetimibe trial with documented statin intolerance.
    • Statin intolerance defined as trial of ≥2 statins with statin‑related symptoms.
    Step Therapy

    Nurtec step requirement

    Nurtec acute use requires documentation of trial and failure of a generic triptan (unless contraindicated) before approval for acute therapy; for prevention document migraine day frequency per policy.

    • Acute: document prior triptan trial and failure or contraindication.
    • Prevention: document migraine days/month (4–14).
    Documentation Required

    Prior therapy and objective disease documentation

    For products requiring objective disease documentation, include prior therapy records and disease activity measures as specified (examples: Crohn's/UC shortened‑interval dosing requires two of symptoms, imaging, fecal calprotectin >120, or CRP ≥300 plus trough levels and initial response).

    • Include objective disease measures where required (fecal calprotectin, CRP, imaging).
    • Provide prior therapy trough levels and evidence of initial response when relevant.
    Documentation Required

    Amvuttra diagnostic documentation

    Amvuttra initial prior authorization must include genetic confirmation of a TTR mutation and a baseline PND score ≤ IIIb, plus supporting diagnostic evidence (biopsy/genetic testing or radionuclide imaging with Grade 2–3 uptake if used).

    • Submit genetic test confirming TTR mutation.
    • Provide baseline PND score ≤ IIIb and supporting diagnostic documentation.
    Documentation Required

    Arikayce microbiology and treatment history

    For Arikayce initial PA, submit a sputum culture confirming MAC lung disease and documentation of ≥6 months of multidrug background regimen with failure to obtain negative sputum cultures; reauthorization requires a negative sputum culture within 30 days.

    • Attach sputum culture supporting MAC diagnosis.
    • Provide prior multidrug regimen details and evidence of failure after ≥6 months.
    • For reauth, supply negative sputum culture within prior 30 days.
    Documentation Required

    Benlysta disease severity and biopsy documentation

    Benlysta initial PA requires a SELENA‑SLEDAI score ≥6 and either anti‑dsDNA >30 IU/mL or ANA >1:80; for lupus nephritis include kidney biopsy confirming class 3, 4, and/or 5 disease and evidence of standard LN therapy.

    • Provide SELENA‑SLEDAI ≥6 and anti‑dsDNA >30 IU/mL or ANA >1:80 for SLE.
    • For LN, include kidney biopsy class and documentation of standard LN therapy.
    Documentation Required

    BRAF V600 mutation documentation

    Braftovi prior authorization must include documentation of BRAF V600 mutation status.

    • Attach BRAF V600 mutation test results to the PA request.
    Documentation Required

    Topical steroid plus calcipotriene trial

    For calcipotriene‑betameth suspension PA, document trial and inadequate response to a generic topical steroid for the scalp in combination with generic calcipotriene solution.

    • Provide details of topical steroid trial (agent, duration) and outcome.
    • Include trial of generic calcipotriene solution and inadequate response documentation.
    Documentation Required

    Caplyta prior therapy documentation

    Caplyta PA requests must include documentation of prior therapies and responses appropriate to the indication (e.g., trials of specified generic atypical antipsychotics for schizophrenia) and patient age (must be ≥18 where required).

    • Provide prior therapy trials with dates, doses, and outcomes.
    • Confirm patient meets age and indication requirements per product entry.
    Documentation Required

    Colistimethate infection documentation

    Colistimethate PA must include culture/susceptibility or local epidemiology supporting use for suspected/proven susceptible bacteria and must document IV or IM use (nebulized/inhalation not covered); prescriber should be or consult an infectious disease specialist.

    • Attach culture & susceptibility results or local epidemiology justification.
    • Confirm route: IV or IM only; inhalation/nebulization is excluded.
    • Document infectious disease specialist involvement.
    Documentation Required

    Cortrophin prerequisite trials and reauth

    Cortrophin PA requires documentation of prerequisite trials (e.g., parenteral glucocorticoid plus another agent depending on indication), adherence to FDA dosing limits, and reauthorization requires demonstrated clinical benefit.

    • Provide records of required prior parenteral glucocorticoid and other specified trials.
    • Quantity limited to FDA‑approved dosing; include rationale and evidence of benefit for reauth.
    Documentation Required

    Cosentyx prior therapy documentation

    Cosentyx PA must include documentation of prior therapies/responses and specialist involvement; do not combine Cosentyx with other biologics, Otezla, or JAK inhibitors and follow indication‑specific prior trial requirements (e.g., NSAID for AS, traditional immunomodulator for psoriasis).

    • Provide prior therapy history and outcomes; prescriber should be a specialist or consult one.
    • Confirm no concurrent excluded biologic/JAKi/Otezla use.
    • Document condition‑specific prior trial(s) as required.
    Documentation Required

    Dihydroergotamine prerequisite trials

    Dihydroergotamine nasal PA requires documentation of trial and failure of one non‑oral triptan (e.g., sumatriptan nasal/injection) and trial/failure of Nurtec ODT before approval.

    • Document non‑oral triptan trial and outcome.
    • Document Nurtec ODT trial and outcome.
    Documentation Required

    Duloxetine trial and failure documentation

    Drizalma/duloxetine‑related product PA must include documentation of inability to use duloxetine (generic) and trial/failure of one other generic antidepressant.

    • Provide reason duloxetine cannot be used.
    • Document trial of another generic antidepressant and inadequate response or intolerance.
    Documentation Required

    Dupixent indication-specific documentation

    Dupixent PA requests need condition‑specific documentation (e.g., blood eosinophils for asthma, esophageal biopsy ≥15 eos/HPF for EoE, topical steroid trials for AD); reauthorization requires demonstrated clinical benefit versus baseline.

    • Include labs/biopsy/imaging as required by indication (e.g., eosinophils, EoE biopsy).
    • Document prior therapy trials and outcomes per indication.
    • Provide evidence of benefit for reauthorization.
    Documentation Required

    Ebglyss prior therapy documentation

    Ebglyss initial PA for atopic dermatitis requires confirmation of moderate‑to‑severe AD and documented trial/failure of Rinvoq and Dupixent; reauthorization requires documentation of positive clinical response and maintenance dosing details.

    • Confirm moderate-to-severe AD and include clinical exam/findings.
    • Provide evidence of Rinvoq and Dupixent trials and inadequate response or intolerance.
    • For reauth, document clinical improvement and specify maintenance dosing schedule.
    Documentation Required

    Diagnosis and prior therapy documentation

    Provide diagnosis confirmation and prior trial/failure documentation as required by the product (examples: chronic urticaria >6 weeks plus one H1 antihistamine; bullous pemphigoid with steroid and steroid‑sparing agent trials).

    • Attach diagnostic evidence and records of prior therapy trials with dates/outcomes.
    • Use policy definitions for 'trial and failure' when documenting.
    Documentation Required

    Fasenra required labs and prior therapy

    Fasenra PA must include blood eosinophil lab results meeting policy thresholds (≥150 cells/µL within 6 weeks OR ≥300 cells/µL in prior 12 months) and documentation of trial/failure of an ICS/LABA within the past 6 months.

    • Submit recent blood eosinophil count per threshold.
    • Provide details of ICS/LABA trial and inadequate response.
    Documentation Required

    Evrysdi documentation

    Evrysdi PA for SMA requires genetic test confirmation of the diagnosis and documentation that the patient is not receiving Spinraza or gene therapy (Zolgensma); reauthorization requires evidence of positive clinical response compared to baseline.

    • Attach genetic testing confirming SMA.
    • Confirm patient is not receiving Spinraza or prior/planned gene therapy.
    • For reauth, submit measures showing clinical improvement or slowed progression.
    Documentation Required

    Growth hormone documentation

    Growth hormone PA for children requires an untreated growth velocity curve ≥1 year showing growth velocity <10th percentile for bone age and gender, bone age at least 1 year behind chronological age (with exceptions), and GH deficiency confirmation by two stimulation tests or equivalent labs; prescriber must be a specialist.

    • Submit untreated growth velocity curve (≥1 year) and bone age data.
    • Provide GH stimulation test results or equivalent IGF‑1/IGFBP3 findings.
    • Prescriber must be endocrinologist, gastroenterologist, or nephrologist.
    Documentation Required

    HAE diagnostic labs

    For HAE products, include C4, C1‑INH protein, and C1‑INH function lab results confirming the diagnosis when submitting prior authorization.

    • Attach C4, C1‑INH protein, and C1‑INH function test results.
    • Ensure prescriber specialty requirement is met (HAE‑experienced specialist).
    Documentation Required

    IVIG dosing documentation

    IVIG prior authorization must include current weight, requested dose, documentation that dosing follows FDA labeling or accepted standards, and note that dose should be adjusted if BMI ≥30 or actual body weight ≥20% above ideal; IVIG is not covered for chronic/routine use in stable myasthenia gravis (only acute myasthenic crisis).

    • Provide current weight and requested dose with dosing rationale.
    • Document adherence to FDA label or accepted standards; adjust dosing if BMI ≥30 or weight ≥20% above ideal.
    • For myasthenia gravis, IVIG covered only for acute crisis with decompensation.
    Documentation Required

    IDH2 mutation documentation

    IDHIFA prior authorization must include documentation of an IDH2 mutation.

    • Attach molecular testing confirming IDH2 mutation.
    Documentation Required

    Documentation for levetiracetam formulation

    For levetiracetam disintegrating/soluble tablets, include medical records documenting inability to use the generic tablet and trial/failure of one other generic anticonvulsant.

    • Document why generic tablet is not usable (e.g., dysphagia).
    • Provide trial/failure record for one other generic anticonvulsant.
    Documentation Required

    Livtencity documentation requirements

    Livtencity PA must include baseline CMV DNA confirming diagnosis and documentation of prior antiviral trial/failure; reauthorization requires documentation of response such as CMV DNA levels; do not co‑administer other CMV antivirals.

    • Submit baseline CMV DNA level and prior antiviral history (ganciclovir, valganciclovir, cidofovir, foscarnet).
    • Do not use concurrently with other CMV antivirals; include response data for reauth.
    Documentation Required

    LDL-C and prior therapy documentation

    Nexletol/Nexlizet prior authorization requires submission of the most recent LDL‑C and documentation of prior therapies and responses (trial of high‑intensity statin + ezetimibe ≥4 weeks or statin intolerance documented by trial of ≥2 statins); include the LDL value and therapy history.

    • Attach most recent LDL‑C value (policy threshold ≥70 mg/dL).
    • Provide dates and outcomes of statin/ezetimibe trials or documented statin intolerance.
    Documentation Required

    Nulibry genetic testing and reauth

    Nulibry prior authorization requires confirmed diagnosis of MoCD Type A by genetic testing (submit results); reauthorization requires documentation of beneficial response in neurological, motor, or developmental measures.

    • Attach genetic test results confirming MoCD Type A.
    • For reauth, provide measures demonstrating clinical benefit versus baseline.
    Documentation Required

    Mercaptopurine formulation documentation

    Mercaptopurine oral suspension PA requires documentation supporting inability to use the generic mercaptopurine tablet.

    • Provide medical justification why the tablet formulation cannot be used.
    Documentation Required

    HRCT documentation

    For indications that require HRCT (e.g., pirfenidone, nintedanib, other ILD agents), include High‑Resolution CT imaging confirming the diagnosis; absence of HRCT may trigger denial.

    • Attach HRCT demonstrating diagnosis per product requirements.
    • Lack of HRCT documentation may lead to denial.
    Documentation Required

    Genetic testing for Orkambi

    Orkambi prior authorization requires laboratory confirmation of homozygous F508del CFTR mutation; include the genetic test in the PA.

    • Submit genetic testing confirming homozygous F508del mutation.
    Documentation Required

    Radicava clinical documentation

    Radicava initial PA requires documentation of definite or probable ALS per revised El Escorial/Arlie House criteria, diagnosis within 2 years, baseline ALSFRS‑R score ≥24, and %FVC ≥80%; reauthorization must show evidence that Radicava is slowing progression.

    • Attach ALS diagnostic criteria documentation and timelines.
    • Provide baseline ALSFRS‑R and %FVC values meeting thresholds.
    Documentation Required

    Revcovi monitoring data

    For Revcovi prior authorization include trough plasma ADA activity and trough dAXP levels, current weight, requested dose, and provider attestation regarding dose adjustment to achieve target monitoring parameters.

    • Provide trough ADA activity and trough dAXP monitoring data.
    • Include weight, requested dose, and attestation to monitoring/adjustment plan.
    Documentation Required

    Rezdiffra documentation

    Rezdiffra initial PA must include MASH diagnosis with biopsy or NIT evidence of fibrosis stage F2–F3, current weight, FDA‑aligned dosing (80 mg/day if <100 kg; 100 mg/day if ≥100 kg), and provider attestation that therapy will be used with diet and exercise; missing these items may trigger denial.

    • Submit biopsy or NITs documenting F2–F3 fibrosis and current weight.
    • Confirm dosing per weight cutoffs and include provider attestation for diet/exercise.

    Initial Therapy Criteria (Selected Products)

    Continuation / Reauthorization Criteria

    Step Therapy Requirements

    Required prior/concurrent therapy
    SELENA-SLEDAI score >=6 and either anti-dsDNA >30 IU/mL or ANA >1:80; taking two of steroid, immunosuppressant, and/or hydroxychloroquine for >=12 weeks each
    For lupus nephritis: kidney biopsy confirming class 3, 4, and/or 5 disease AND receiving standard LN therapy (e.g., mycophenolate or azathioprine plus a steroid)
    Prior therapy requirement
    Must try and fail an SSRI or SNRI (>=4 weeks) and one atypical antidepressant (e.g., bupropion, mirtazapine) before Auvelity
    Step therapy completion examples
    Calcipotriene-betameth: trial and failure with a generic topical steroid for the scalp plus generic calcipotriene solution
    Brivaracetam: trial and failure with generic levetiracetam and at least one other generic anticonvulsant
    Cortrophin: trial of a parenteral glucocorticoid plus one other medication for the condition (infantile spasms exempt)
    Dihydroergotamine nasal: trial and failure of one non-oral triptan AND trial and failure of Nurtec ODT
    Drizalma/duloxetine-related: inability to use duloxetine AND trial and failure with one other generic antidepressant
    Dupixent (EOE): PPI or swallowed topical steroid >=2 months then persistent symptoms and biopsy >=15 eos/HPF
    Ebglyss for AD: trial and failure to Rinvoq AND trial and failure to Dupixent
    General biologics (RA, PsO, AS): try and fail one traditional non-biologic immunomodulator or condition-specific first-line agent
    Atopic dermatitis step requirement
    Confirmation of moderate-to-severe atopic dermatitis AND trial and failure to Rinvoq AND trial and failure to Dupixent prior to coverage
    Required prior antidepressant trials for MDD
    Trial and failure with two generic antidepressants from different classes
    One of the two must be either bupropion or mirtazapine
    Traditional immunomodulator trial before biologics
    For RA and psoriasis: trial and failure of one traditional non-biologic immunomodulator (e.g., methotrexate, leflunomide, cyclosporine) required prior to many biologics
    For ankylosing spondylitis: trial and failure of one NSAID required prior to biologic therapy
    Kerendia prior therapy / evidence
    For HF (LVEF >=40%): patient must be on at least two standard heart failure medications from different classes at appropriate doses and prescribed by/with cardiology involvement
    For CKD with T2DM: must have tried an SGLT2 inhibitor or GLP-1 RA unless intolerant/contraindicated and be on maximally tolerated ACEI or ARB
    Levetiracetam disintegrating tablet step flag
    Must document inability to use generic levetiracetam tablet AND trial and failure with one other generic anticonvulsant before approval
    Nexletol / Nexlizet step requirement
    Submit most recent LDL-C; must have tried high-intensity statin plus ezetimibe >=4 weeks with LDL-C >=70 mg/dL OR tried ezetimibe >=4 weeks with documented statin intolerance after >=2 statins
    Must not be used with PCSK9 inhibitors or Juxtapid
    NURTEC acute step requirement
    For acute NURTEC: unless contraindicated, patient must try and fail one generic triptan prior to approval
    Step therapy yes/no (aggregated examples)
    Yes — many products require completion of specified prior trials and documentation of failure/intolerance (examples: biologics, Nexletol/Nexlizet, Livtencity, levetiracetam disintegrating tablet)
    Yes — acute NURTEC requires prior triptan trial unless contraindicated
    Yes — certain antidepressant and antipsychotic products require multiple generic trials (see product-specific rules)
    Antipsychotic / other step requirements
    Secuado and similar antipsychotic step: trial and failure with two generic antipsychotics (each >=28 days) required
    Other products: product-specific step trials of generics required prior to branded alternatives (see individual entries)
    Sodium oxybate prior stimulant/modafinil trials
    Must try and fail amphetamine salts/dextroamphetamine/methylphenidate AND modafinil or armodafinil prior to sodium oxybate coverage
    Branded antidepressant step examples
    Some branded antidepressants require trial and failure of two generic antidepressants (SSRIs, SNRIs, bupropion, mirtazapine or trazodone) before approval
    Documentation must show inability to improve depressive symptoms after at least 4 weeks on each agent
    Biologic prior therapy example (ustekinumab-aekn)
    For psoriasis biologics (e.g., ustekinumab-aekn): trial and failure of one traditional non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) required prior to coverage
    Aggregated required prior therapy trials (examples)
    Winrevair (PAH): trial and failure of dual therapy with a PDE5 inhibitor AND an endothelin receptor antagonist required prior to Winrevair add-on
    Xeljanz (and other JAKi/biologics): must not be used with other biologics/Otezla/JAKis and often require trial of a traditional non-biologic immunomodulator for RA
    Various anticonvulsant / CNS agents: require documented trials of specified generics or alternative therapies before branded formulations

    Quantity Limits and Dosing Constraints

    IVIG dosing — weight-adjusted dosing rules and BMI considerations (inv-302)
    IVIG dosing — weight adjustment ruleDosing must follow FDA labeling or accepted standards; provide current weight and requested dose
    BMI/weight considerationDose must be weight-adjusted if BMI >= 30 or actual body weight is >= 20% above ideal body weight
    Documentation requiredMedical records supporting the diagnosis and dose must be submitted
    OJEMDA oral suspension (reconstituted) — 1 box limit (inv-303)
    OJEMDA oral suspension (reconstituted) quantity limit1 box per 28 days (limited to 1 box)
    IndicationOral suspension covered only when patient unable to swallow tablet formulation
    Coverage durationOne year authorization
    Radicava ORS — initial and maintenance ORS quantity limits (inv-304)
    Radicava ORS initial and maintenance limits70 mL first 28 days, then 50 mL every 28 days thereafter
    Coverage duration12 months initial authorization
    Initial documentationALS diagnosis, ALSFRS-R >=24, diagnosis <=2 years, %FVC >=80% required
    Prevymis oral — total days limit example (inv-305)
    Prevymis oral total days limit200 days total
    Coverage durationApplied per authorization rules in policy (see product entry)
    IndicationsAll medically-accepted indications; documentation as required
    Ojemda oral suspension — 1 box per 28 days (inv-306)
    Ojemda oral suspension quantity limit1 box per 28 days
    Use conditionOral suspension covered when patient cannot swallow tablets
    Authorization lengthOne year
    Scemblix 20 mg — quantity limit example (inv-307)
    Scemblix 20 mg quantity limit60 tablets per 30 days
    Scemblix 40 mg quantity limit240 tablets per 30 days (separate entry)
    PrescriberMust be prescribed by or in consultation with an oncologist/hematologist
    Scemblix 40 mg — quantity limit example (inv-308)
    Scemblix 40 mg quantity limit240 tablets per 30 days
    Related requirementMutation documentation may be required for specific indications
    Coverage durationOne year
    tolvaptan dosing limits — hyponatremia vs ADPKD maximums (inv-309)
    Tolvaptan dosing limitsUp to 60 mg/day for hyponatremia; up to 120 mg/day for ADPKD
    Indication-specific sodium thresholdHyponatremia: serum sodium <125 mEq/L required for hyponatremia indication
    Coverage durationsHyponatremia: 30 days; ADPKD: 2 years
    VOWST — single treatment course limit (inv-310)
    VOWST quantity limitOne treatment course: 12 capsules over 3 days
    IndicationTreatment course limited to indicated CDI episodes meeting policy criteria
    AuthorizationOne treatment course per authorization as specified
    Xifaxan — IBS-D and TD course/duration limits (inv-311)
    Xifaxan quantity limitsIBS-D: up to three 14-day courses; TD: up to three days
    Prerequisite trialsTD requires trial/failure with azithromycin; hepatic encephalopathy requires trial/failure with lactulose
    SIBO coverage stanceSIBO is explicitly not covered
    Zurzuvae — one treatment course per year limit (inv-312)
    Zurzuvae quantity limitOne treatment course per year
    IndicationApplied per product-specific criteria in policy
    Authorization durationOne year initial and reauthorization as specified

    Site of Care and Prescriber Qualifications

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background and Scope

    This extract summarizes Priority Health Medicare prior authorization rules for pharmacy and specialty drugs. It sets the scope for coverage decisions including indication‑specific eligibility, required documentation (diagnostic tests, prior‑therapy trials, laboratory thresholds), prescriber or specialist requirements, quantity and site‑of‑care constraints, and explicit exclusions (for example, combination biologic/JAKi prohibitions and administration route exclusions). The policy applies to listed specialty and pharmacy products and requires prior authorization with submission of the supporting clinical documentation described in each product section.

    Definitions and Clinical Thresholds

    PND score definition for HATTR-PN (inv-244)
    PND score definitionPolyneuropathy Disability (PND) score used to stage neuropathy severity; baseline requirement <= IIIb for HATTR-PN initial coverage
    UseRequired as part of Amvuttra initial diagnostic documentation
    AgeApplies to adults (age >=18) in policy entry
    SELENA-SLEDAI definition for SLE activity (inv-245)
    SELENA-SLEDAI definitionDisease activity index for SLE; a score of ≥ 6 required for Benlysta SLE initial requests
    Additional serology requirementAnti-dsDNA >30 IU/mL OR ANA >1:80 required along with SELENA-SLEDAI
    Therapy contextMust be taking two of steroid, immunosuppressant, hydroxychloroquine for >=12 weeks each prior to initiation
    EOE biopsy eosinophil threshold definition (inv-246)
    EOE biopsy threshold definitionDiagnosis confirmed by esophageal biopsy with at least 15 eosinophils per high power field (HPF)
    Associated clinical criteriaPersistent symptoms despite >=2 months PPI and trial of topical steroid >=2 months
    AgeApplies to patients age >=11 years per policy
    Severe eosinophilic asthma lab thresholds definition (inv-247)
    Severe eosinophilic asthma lab thresholdsBlood eosinophils >=150 cells/μL within 6 weeks or >=300 cells/μL in prior 12 months
    ContextUsed to determine eligibility for biologic therapy (e.g., Fasenra, Dupixent) for eosinophilic phenotype
    Additional requirementTrial/failure of ICS/LABA in past 6 months required
    GHD confirmation — growth hormone deficiency definition (inv-248)
    GHD confirmation definitionFor children: growth velocity and bone age criteria plus GH stimulation tests or low IGF-1/IGFBP3; for adults: suboptimal GH-stimulation test or persistent childhood-onset GHD or pituitary/hypothalamic disease with >=3 pituitary hormone deficits and low IGF-1
    Required documentationUntreated growth velocity curve >=1 year and bone age data required for pediatric requests
    PrescriberMust be prescribed by endocrinologist, gastroenterologist, or nephrologist
    Try and fail definition as used in the policy (inv-249)
    Try and fail definitionDefined as intolerance or inability to improve symptoms with a prior therapy
    Policy useApplied across step therapy and prerequisite therapy requirements in multiple product entries
    DocumentationMedical records must document trial duration and reason for failure/intolerance
    HRCT confirming diagnosis definition (inv-250)
    HRCT confirming diagnosis definitionHigh-resolution computed tomography required to confirm diagnoses such as IPF or other ILD where specified
    UseRequired documentation for coverage of OFEV/nintedanib-class agents and related ILD indications
    Additional requirementPrescriber must rule out other known causes of interstitial lung disease
    MoCD Type A definition for Nulibry (inv-251)
    MoCD Type A definitionMolybdenum cofactor deficiency Type A — diagnosis must be confirmed by genetic testing
    DocumentationGenetic testing results must be submitted for Nulibry initial and reauthorization requests
    Reauthorization evidenceDemonstrate benefit in neurological or developmental measures compared to baseline
    ALSFRS-R definition and baseline requirement for Radicava (inv-252)
    ALSFRS-R definitionRevised ALS Functional Rating Scale; baseline requirement: minimum total score 24 (>=2 points on each of 12 items)
    Use for RadicavaRequired documentation for Radicava initial requests along with %FVC >=80% and diagnosis <=2 years
    ReauthorizationDocumentation that Radicava is slowing ALS progression required
    FEV1 and AAT level definition for augmentation therapy (inv-253)
    FEV1 and AAT level definitionFEV1 < 80% predicted AND serum AAT < 11 micromoles/L (80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry)
    IndicationRequired criteria for augmentation therapy (Prolastin-C)
    DocumentationSubmit pulmonary function testing and AAT serum level results
    MASH (metabolic dysfunction-associated steatohepatitis) definition (inv-254)
    MASH definitionMetabolic dysfunction-associated steatohepatitis (MASH) — diagnosis required for Rezdiffra requests
    Fibrosis stagingModerate to advanced fibrosis consistent with F2 or F3 required, confirmed by biopsy or NITs
    PrescriberMust be prescribed by or in consultation with a gastroenterologist or hepatologist
    Birmingham Vasculitis Activity Score (BVAS) definition (inv-255)
    BVAS definitionBirmingham Vasculitis Activity Score used to document disease activity and required reduction for Tavneos reauthorization
    UseRequired evidence of BVAS reduction and steroid dose reduction for Tavneos reauthorization
    PrescriberMust be prescribed by or in consultation with a specialist
    Hypogonadism documentation definition (inv-256)
    Hypogonadism documentation definitionTwo morning pre-treatment total testosterone measurements on separate days <300 ng/dL (or low per lab ref) plus clinical signs/symptoms other than erectile dysfunction/decreased libido
    Clinical examplesDepressed mood, decreased energy, progressive loss of muscle mass, osteoporosis
    Coverage durationTwo years
    Hyponatremia criteria for tolvaptan (inv-257)
    Hyponatremia criteria for tolvaptanHypervolemic or euvolemic hyponatremia with serum sodium <125 mEq/L or symptomatic nonresponse to fluid restriction
    Dosing alignmentTolvaptan dosing limited to FDA-approved quantities depending on indication (up to 60 mg/day hyponatremia; up to 120 mg/day ADPKD)
    DocumentationConfirm serum sodium and clinical context when requesting tolvaptan
    Trial and failure definition (baseline) (inv-258)
    Trial and failure definition (baseline)Defined as an intolerance or inability to improve the condition on the required therapy
    Policy applicationUsed across many prior therapy and step therapy requirements in the document
    DocumentationMedical records must document trial duration and outcome
    Baseline definition for IgE and allergy testing (inv-259)
    Baseline for IgE and testingDefined as before treatment with Xolair or another therapy that lowers IgE levels
    Baseline IgE numeric requirement>= 30 IU/mL for many Xolair indications
    DocumentationProvide baseline IgE and current weight at initiation and reauthorization
    Drug index entry definition and usage (inv-260)
    Drug index entry definitionIndex/listing entries include product name, formulation, dosage strength, pack type, and occasional page/part references
    PurposeUsed for quick lookup; index entries do not themselves state PA rules
    LocationIndex appears in the last parts of the document (part 10-11) per source